U.S. markets open in 7 hours 19 minutes
  • S&P Futures

    4,218.75
    +9.00 (+0.21%)
     
  • Dow Futures

    33,357.00
    +53.00 (+0.16%)
     
  • Nasdaq Futures

    13,351.50
    +40.25 (+0.30%)
     
  • Russell 2000 Futures

    1,981.90
    +5.60 (+0.28%)
     
  • Crude Oil

    93.88
    -0.46 (-0.49%)
     
  • Gold

    1,806.30
    -0.90 (-0.05%)
     
  • Silver

    20.35
    +0.01 (+0.03%)
     
  • dólar/euro

    1.0323
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • dólar/libra

    1.2199
    -0.0004 (-0.03%)
     
  • yen/dólar

    133.2550
    +0.2560 (+0.19%)
     
  • BTC-USD

    23,977.12
    -607.99 (-2.47%)
     
  • CMC Crypto 200

    569.67
    -5.08 (-0.88%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,513.39
    +694.06 (+2.49%)
     

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Editas Medicine, Inc.
Editas Medicine, Inc.

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Mei as an inducement material to Dr. Mei entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 171,602 shares of Editas Medicine common stock at a price of $14.99 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Mei’s employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Mei’s continued service relationship with Editas Medicine through the applicable vesting dates. 

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 cristi.barnett@editasmed.com Investors Ron Moldaver (617) 401-9052 ir@editasmed.com